Emma Walmsley became the chief executive of GlaxoSmithKline 22 months ago, looking like the opposite of a pharma insider: She was, instead, steeped in the business of selling toothpaste and Tums. Appearances may have been deceiving — because she’s betting on drugs.

Walmsley had run Glaxo’s consumer business for five years, and had previously worked for 17 years at L’Oréal. But if her tenure at the helm of Glaxo so far makes one thing clear, it’s that she is now all-in on pharma. In three years she plans to spin off the same consumer business she ran after merging it with Pfizer’s unit that sells Listerine and ChapStick, and, by the way, larding the new company with accumulated debt she’s sure it can quickly pay off.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have been trying since last September to obtain the vaccine Shingrix for myself and husband. CVS and Walgreens in my area,(Millis and Medway Mass)have repeatedly informed me that deliveries of this vaccine are few and far between. The GSK company has made promises that substantial deliveries are on the way. There have been no such deliveries; not in this area anyway. Now we are being told that deliveries of this vaccine will start in May 2019.
    I hope we don’t develope shingles in the meantime. It has been a very long wait and will continue for the second dose. Poor management and very poor communication.

  • ‘Last October, Glaxo decided it will once again pay physicians for speaking for the first two years some products are marketed. “It’s absolutely critical that physicians can talk to peers,” Miels said.‘

    That’s totally what the $ is for. Because physicians can’t talk to each other without getting paid by Pharma….

  • Listerine is sold J&J Product. Pfizer sold their consumer products to J&J and acquired consumer products through Wyeth purchase. Those consumer products are being combined with GSK Consumer Products and going to be spun-off.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy